Last reviewed · How we verify
NCT03108794
A Nation-wide Hospital-based Hepatitis B Registry:China Registry of Hepatitis B
trial in Chronic Hepatitis B in 200,000 participants. Status unknown.
31 December 2022
Quick facts
| Lead sponsor | Beijing Friendship Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 200,000 |
| Start date | 30 June 2012 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 December 2025 |
| Sites | 45 locations across China |
Conditions studied
- Chronic Hepatitis B — all drugs for Chronic Hepatitis B →
Sponsor
Beijing Friendship Hospital
Who can join
Eligibility, any sex, with Chronic Hepatitis B. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
CR-HepB registry started in June 30,2012 to collect HBV cases from general hospitals or specialized hospitals for infectious diseases in mainland China. Demographics, diagnosis, laboratory test results, family history and prescriptions were recorded. The main criteria for registration is HBsAg-positivity more than 6 months, and these patients will receive followed-up visits every three to six months.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Baseline Characteristics and Treatment Patterns of the Patients Recruited to the China Registry of Hepatitis B.
Shan S, You H, Niu J, Shang J, et al · · 2019 · cited 16× · PMID 31915601 · DOI 10.14218/jcth.2019.00052 -
Risk of HCC decreases in HBV-related patients with cirrhosis acquired recompensation: A retrospective study based on Baveno VII criteria.
Zhang Y, Liu X, Li S, Lin C, et al · · 2024 · cited 13× · PMID 38126951 · DOI 10.1097/hc9.0000000000000355 -
Role of nutritional status and nutritional support in outcome of hepatitis B virus-associated acute-on-chronic liver failure.
Chang Y, Liu QY, Zhang Q, Rong YM, et al · · 2020 · cited 12× · PMID 32848334 · DOI 10.3748/wjg.v26.i29.4288 -
China Registry of Hepatitis B (CR-HepB): Protocol and implementation of a nationwide hospital-based registry of hepatitis B.
Shan S, Wei W, Kong Y, Niu J, et al · · 2020 · cited 5× · PMID 29716439 · DOI 10.1177/1403494818772188 -
[Comparison of the population covered by the 2024 version of the WHO's hepatitis B prevention and treatment guidelines and the Chinese antiviral treatment guidelines].
Wang BQ, Shan S, Kong YY, Wu XN, et al · · 2024 · cited 1× · PMID 38964895 · DOI 10.3760/cma.j.cn501113-20240421-00218 -
[Ten-year changes in clinical characteristics and antiviral treatment patterns of chronic hepatitis B in China: a CR-HepB-based real-world study].
Xu XQ, Wang H, Shan S, You H, et al · · 2023 · cited 1× · PMID 37580251 · DOI 10.3760/cma.j.cn501113-20230518-00226 -
Nonlinear relationship between age and the risk of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis.
Zhang Y, Wang Y, Jiao S, Li S, et al · · 2025 · PMID 41272517 · DOI 10.1186/s12879-025-12016-9 -
[Distribution characteristics of serum HBsAg levels in Chinese patients with chronic hepatitis B based on CR-HepB].
Chen SY, Shan S, Kong YY, Xu XQ, et al · · 2025 · PMID 39929682 · DOI 10.3760/cma.j.cn501113-20240723-00337
Verify or expand the search:
- PubMed search for NCT03108794
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Hepatitis B
Currently open trials in the same condition.
- NCT07275918 — SA1211 Injection Phase 1 Study · Phase 1 · recruiting
- NCT04843852 — TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B · Phase 1 · recruiting
- NCT07135349 — A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B · Phase 2 · active not recruiting
- NCT07307586 — A Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatiti · Phase 3 · recruiting
- NCT07246889 — Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE) · Phase 3 · active not recruiting
Other Beijing Friendship Hospital trials
Trials by the same sponsor.
- NCT07453862 — Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety · Phase 1 · recruiting
- NCT07397442 — Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
- NCT07393048 — Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant The · recruiting
- NCT07441850 — Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy · NA · recruiting
- NCT07369739 — Golidocitinib Combined With Selinexor for CAEBVD · Phase 2, PHASE3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03108794 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Friendship Hospital
- Last refreshed: 6 November 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03108794.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing